The company, which held a press conference last Wednesday, April 29, detailed its latest results, asserting that it is now operating with full normality. This improvement is part of the completion of a transformation process initiated in September 2023.
“"We are satisfied to say that we are now out of the hospital, completely out. The company is developing a completely normal pace and life."
Executives emphasized that the current figures are
“"consolidated. They are not a flash in the pan, not at all."
During the first quarter of 2026, the company recorded an EBITDA of 135 million euros, 15% higher than the 117 million of the previous year. The sales margin stood at 16%. These results contrast with the losses of 143 million euros in 2025, which already represented a 49% reduction compared to the 281 million in 2024.
Furthermore, the company invested 183 million euros last year, 60% more than in previous years. This investment was fully financed with own funds, partly thanks to several capital increases, and is being actively applied in all plants, especially in Spain.
